SG11201407416XA - Use of semaphorin-4d binding molecules to promote neurogenesis following stroke - Google Patents
Use of semaphorin-4d binding molecules to promote neurogenesis following strokeInfo
- Publication number
- SG11201407416XA SG11201407416XA SG11201407416XA SG11201407416XA SG11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA SG 11201407416X A SG11201407416X A SG 11201407416XA
- Authority
- SG
- Singapore
- Prior art keywords
- semaphorin
- binding molecules
- following stroke
- promote neurogenesis
- neurogenesis following
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646119P | 2012-05-11 | 2012-05-11 | |
US13/842,523 US10494440B2 (en) | 2012-05-11 | 2013-03-15 | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
PCT/US2013/040661 WO2013170221A1 (fr) | 2012-05-11 | 2013-05-10 | Utilisation de molécules de liaison de sémaphorine 4d pour stimuler la neurogenèse après un accident vasculaire cérébrale |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407416XA true SG11201407416XA (en) | 2015-03-30 |
Family
ID=49548777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407416XA SG11201407416XA (en) | 2012-05-11 | 2013-05-10 | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke |
Country Status (18)
Country | Link |
---|---|
US (1) | US10494440B2 (fr) |
EP (1) | EP2846831B1 (fr) |
JP (1) | JP6218810B2 (fr) |
KR (1) | KR102105436B1 (fr) |
CN (2) | CN110064054A (fr) |
AU (1) | AU2013259192B2 (fr) |
BR (1) | BR112014028160B1 (fr) |
CA (1) | CA2872928C (fr) |
DK (1) | DK2846831T3 (fr) |
EA (1) | EA030796B1 (fr) |
ES (1) | ES2882881T3 (fr) |
IL (1) | IL235603B (fr) |
MX (1) | MX358991B (fr) |
NZ (1) | NZ630864A (fr) |
PT (1) | PT2846831T (fr) |
SG (1) | SG11201407416XA (fr) |
WO (1) | WO2013170221A1 (fr) |
ZA (1) | ZA201501674B (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG175417A1 (en) | 2009-05-08 | 2011-12-29 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
JP6395606B2 (ja) | 2011-10-11 | 2018-09-26 | バクシネックス インコーポレーティッド | 血液脳関門透過性の調節のためのセマフォリン−4d結合分子の使用 |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
DK3013350T3 (da) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
WO2017184951A1 (fr) | 2016-04-22 | 2017-10-26 | Vaccinex, Inc. | Présentation de protéine transmembranaire sur des virions à enveloppe extracellulaire de poxvirus |
MX2019001453A (es) | 2016-08-02 | 2019-06-20 | Vaccinex Inc | Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. |
RU2766341C2 (ru) * | 2017-02-22 | 2022-03-15 | Вакцинекс, Инк. | Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях |
JP7246320B2 (ja) | 2017-05-05 | 2023-03-27 | バクシネックス インコーポレーティッド | ヒト抗セマフォリン4d抗体 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
SI1325932T1 (fr) | 1997-04-07 | 2005-08-31 | Genentech Inc | |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
AU6897998A (en) | 1997-04-11 | 1998-11-11 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-rela ted antigens |
EP0892047A3 (fr) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Semaphorine L humaine et murine |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
WO2000028016A1 (fr) | 1998-11-10 | 2000-05-18 | University Of Rochester | Lymphocytes t specifiques d'antigenes cible, vaccins prepares a partir desdits lymphocytes, et methodes associees |
JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
EP1365018A1 (fr) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Function de la sémaphorine CD100 dans la myélination |
DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
EP1442749A1 (fr) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation d'un anticorps anti-CD100 pour le traitement et le diagnostic d'une maladie inflammatoire du système nerveux central |
KR20060006975A (ko) | 2003-05-30 | 2006-01-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
EP2336178A1 (fr) | 2003-12-11 | 2011-06-22 | Genentech, Inc. | Procédés et compositions pour l'inhibition de dimérisation et activation C-Met |
CA2554735A1 (fr) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Molecules porteuses et therapeutiques |
US20060003452A1 (en) * | 2004-07-01 | 2006-01-05 | Virxsys Corporation | Vector packaging cell line |
CN104804095A (zh) | 2004-08-05 | 2015-07-29 | 健泰科生物技术公司 | 人源化抗c-met 拮抗剂 |
US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
JP2008535856A (ja) | 2005-04-07 | 2008-09-04 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | 癌の診断、検出および治療におけるsema4d |
JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
PE20091378A1 (es) | 2008-01-10 | 2009-10-14 | Genentech Inc | Polipeptidos agonistas plexind1 |
AU2010224094A1 (en) * | 2009-03-13 | 2011-09-22 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
SG175417A1 (en) | 2009-05-08 | 2011-12-29 | Vaccinex Inc | Anti-cd100 antibodies and methods for using the same |
DK2429585T3 (en) | 2009-05-15 | 2018-07-30 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY |
NZ604464A (en) | 2010-06-14 | 2014-03-28 | Vaccinex Inc | Anti-vegf antibodies and uses thereof |
ES2640567T3 (es) | 2011-05-13 | 2017-11-03 | National University Corporation Tokyo Medical And Dental University | Promotor de la osteogénesis |
JP6395606B2 (ja) | 2011-10-11 | 2018-09-26 | バクシネックス インコーポレーティッド | 血液脳関門透過性の調節のためのセマフォリン−4d結合分子の使用 |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
DK3013350T3 (da) | 2013-06-25 | 2020-04-14 | Vaccinex Inc | Anvendelse af semaphorin-4D-hæmmende molekyler i kombination med en immunmodulerende terapi for at hæmme tumorvækst og metastaser |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
RU2766341C2 (ru) * | 2017-02-22 | 2022-03-15 | Вакцинекс, Инк. | Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях |
-
2013
- 2013-03-15 US US13/842,523 patent/US10494440B2/en active Active
- 2013-05-10 AU AU2013259192A patent/AU2013259192B2/en active Active
- 2013-05-10 CN CN201910064594.5A patent/CN110064054A/zh active Pending
- 2013-05-10 CA CA2872928A patent/CA2872928C/fr active Active
- 2013-05-10 EP EP13787931.8A patent/EP2846831B1/fr active Active
- 2013-05-10 ES ES13787931T patent/ES2882881T3/es active Active
- 2013-05-10 DK DK13787931.8T patent/DK2846831T3/da active
- 2013-05-10 JP JP2015511789A patent/JP6218810B2/ja active Active
- 2013-05-10 EA EA201492067A patent/EA030796B1/ru not_active IP Right Cessation
- 2013-05-10 SG SG11201407416XA patent/SG11201407416XA/en unknown
- 2013-05-10 PT PT137879318T patent/PT2846831T/pt unknown
- 2013-05-10 CN CN201380037262.9A patent/CN104619341A/zh active Pending
- 2013-05-10 NZ NZ630864A patent/NZ630864A/en unknown
- 2013-05-10 KR KR1020147034510A patent/KR102105436B1/ko active IP Right Grant
- 2013-05-10 MX MX2014013676A patent/MX358991B/es active IP Right Grant
- 2013-05-10 WO PCT/US2013/040661 patent/WO2013170221A1/fr active Application Filing
- 2013-05-10 BR BR112014028160-2A patent/BR112014028160B1/pt active IP Right Grant
-
2014
- 2014-11-10 IL IL235603A patent/IL235603B/en active IP Right Grant
-
2015
- 2015-03-11 ZA ZA2015/01674A patent/ZA201501674B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10494440B2 (en) | 2019-12-03 |
AU2013259192A1 (en) | 2014-11-27 |
US20130302320A1 (en) | 2013-11-14 |
IL235603A0 (en) | 2015-01-29 |
KR20150018555A (ko) | 2015-02-23 |
NZ630864A (en) | 2017-03-31 |
MX2014013676A (es) | 2015-02-05 |
CN110064054A (zh) | 2019-07-30 |
BR112014028160B1 (pt) | 2021-01-12 |
IL235603B (en) | 2020-01-30 |
CA2872928A1 (fr) | 2013-11-14 |
JP2015517502A (ja) | 2015-06-22 |
EP2846831A1 (fr) | 2015-03-18 |
DK2846831T3 (en) | 2021-10-11 |
CA2872928C (fr) | 2021-02-16 |
AU2013259192B2 (en) | 2018-02-22 |
ZA201501674B (en) | 2021-06-30 |
PT2846831T (pt) | 2021-08-19 |
EA201492067A1 (ru) | 2015-05-29 |
WO2013170221A1 (fr) | 2013-11-14 |
MX358991B (es) | 2018-08-31 |
EA030796B1 (ru) | 2018-09-28 |
JP6218810B2 (ja) | 2017-10-25 |
EP2846831A4 (fr) | 2015-11-18 |
CN104619341A (zh) | 2015-05-13 |
ES2882881T3 (es) | 2021-12-03 |
EP2846831B1 (fr) | 2021-07-07 |
KR102105436B1 (ko) | 2020-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201501674B (en) | Use of semaphorin-4d binding molecules to promote neurogenesis following stroke | |
EP2932375A4 (fr) | Adaptation d'opportunité au contexte | |
AP2015008266A0 (en) | 1L-18 binding molecules | |
IL234234B (en) | 2ang binding molecules | |
ZA201406082B (en) | Use of ccr3-inhibitors | |
GB201303603D0 (en) | Improvements relating to valves | |
AP2013007086A0 (en) | Bispecific binding molecules binding to DII4 and Ang2 | |
EP2881113A4 (fr) | Nouvelle application de la pogostone | |
EP2892529A4 (fr) | Utilisations de (-)-perhexiline | |
GB2505689B (en) | Improvements to valve assemblies | |
HK1199410A1 (en) | Composition for enhancing defenses of skin | |
IL229958B (en) | Improvements to pumps and components therefor | |
EP2926078A4 (fr) | Améliorations apportées à des systèmes de visée patridge et procédés associés | |
GB201215007D0 (en) | Improvements in or relating to luminaires | |
GB2507762B (en) | Improvements to dartboards | |
GB201220796D0 (en) | Improvements relating to authentication | |
GB201215288D0 (en) | Improvements relating to firelighters | |
GB201222774D0 (en) | Improvements relating to aution mechanisms | |
GB201222657D0 (en) | Improvements relating to personal tracking identifiers | |
GB201204924D0 (en) | Improvements relating to splitting devices | |
GB201209623D0 (en) | Improvements relating to mobile technology | |
GB201208097D0 (en) | Improvements relating to mobile technology | |
GB201213079D0 (en) | Novel use of aggregates |